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Background: Cerebral amyloid angiopathy (CAA) refers to the deposition of β-amyloid (Aβ) peptides in the wall of
brain vasculature, commonly involving capillaries and arterioles. Also being considered a part of CAA is the Aβ
deposition in leptomeninge. The cellular origin of angiopathic Aβ and the pathogenic course of CAA remain
incompletely understood.
Methods: The present study was aimed to explore the pathogenic course of CAA in the human cerebrum via
examination of changes in β-secretase-1 (BACE1), the obligatory Aβ producing enzyme, relative to Aβ and other
cellular markers, by neuroanatomical and biochemical characterizations with postmortem brain samples and
primary cell cultures.
Results: Immunoreactivity (IR) for BACE1 was essentially not visible at vasculature in cases without cerebral amyloidosis
(control group, n = 15, age = 86.1 ± 10.3 year). In cases with brain amyloid pathology (n = 15, age = 78.7 ± 12.7 year),
increased BACE1 IR was identified locally at capillaries, arterioles and along the pia, localizing to endothelia, perivascular
dystrophic neurites and meningeal cells, and often coexisting with vascular iron deposition. Double immunofluorescence
with densitometric analysis confirmed a site-specific BACE1 elevation at cerebral arterioles in the development of vascular
Aβ deposition. Levels of BACE1 protein, activity and its immediate product (C99) were elevated in leptomeningeal lysates
from cases with CAA relative to controls. The expression of BACE1 and other amyloidogenic proteins in the
endothelial and meningeal cells was confirmed in primary cultures prepared from human leptomeningeal and
arteriolar biopsies.
Conclusion: These results suggest that BACE1 elevation in the endothelia and perivascular neurites may be
involved in angiopathic Aβ deposition, while BACE1 elevation in meningeal cells might contribute Aβ to
leptomeningeal amyloidosis.
Keywords: Amyloidosis, Brain aging, Blood brain barrier, Dementia, NeurodegenerationBackground
β-Amyloid (Aβ) peptide deposition in the brain is com-
monly associated with aging and age-related neurological
diseases. Extracellular Aβ deposition in brain parenchyma,
especially in the form of neuritic plaques, serves as one of
the definitive diagnostic criteria for Alzheimer’s disease
(AD) [1,2]. Aβ deposition can also occur in the wall of* Correspondence: yanxiaoxin@csu.edu.cn
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unless otherwise stated.blood vessels, referred to as cerebral amyloid angiopathy
(CAA). Further, β-amyloidosis may present on the pial
surface, which is also considered a part of CAA. Overall,
CAA coexists frequently with plaque lesions in AD brains
[3]. Also of note, postmortem studies show that vascular
amyloidosis can occur in the brains of non-demented
elderly or patients with vascular dementia and other neu-
rological conditions [4-9]. While CAA may be regarded as
a pathological rather than disease entity, its clinical impact
is increasingly recognized. CAA is frequently associated
with blood brain barrier (BBB) damage and degenerationis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,











(male: 9, female: 6,
age range: 66-95
years)
case 1 5 C IV
case 2 5.5 C V
case 3 6.5 C V
case 4 6 A N/A
case 5 8 B II
case 6 8 A N/A
case 7 5 A II
case 8 3.5 B II
case 9 4.5 B III
case 10 7 B N/A
case 11 3 B V
case 12 5.5 B II
case 13 6 C IV
case 14 4.5 B III
case 15 5 C III
Control group
(male: 9, female: 6,
age range: 58-97
years)
case 1 5 N/A II
case 2 5.5 N/A N/A
case 3 4.5 N/A II
case 4 6.5 N/A I
case 5 6 N/A II
case 6 4 N/A N/A
case 7 7.5 N/A N/A
case 8 5 N/A N/A
case 9 5 N/A N/A
case 10 8 N/A I
case 11 8.5 N/A N/A
case 12 6.5 N/A N/A
case 13 6.5 N/A N/A
case 14 4.5 N/A II
case 15 8 N/A N/A
P value 0.285 N/A: not applicable
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or active hemorrhage, which may cause secondary neur-
onal damage and functional loss [10-14].
The pathogenic mechanism underlying CAA has been
conceptualized largely in context of an abnormal Aβ
conveyance around the neurovascular interface. Many
studies explored the role of reduced brain-to-blood ef-
flux and/or increased periphery-to-central transportation
of Aβ in cerebral amyloidosis e.g., [15-18]. Thus, CAA
may occur as a consequence of interstitial Aβ elevation
in the brain together with impaired drainage of the pep-
tides from parenchyma to blood [19-22]. Retrograde Aβ
transportation from blood into the brain is also consi-
dered to cause vascular amyloidosis, with some studies
explored a role for platelets in Aβ production and the
development of CAA [23,24].
β-Secretatse-1 (BACE1) is the obligatory enzyme known
for its cleavage to the β-amyloid precursor protein (APP)
leading to Aβ production. A role for BACE1 upregulation
in parenchymal plaque pathogenesis has been evaluated
by multiple groups, including us [25,26]. According to
recent cell line [27-29] and postmortem brain studies
[30,31], BACE1 elevation in vascular endothelia and
smooth muscle cells may play a role in the pathogenesis
of CAA. However, evidence for site-specific BACE1 eleva-
tion relative to angiopathic Aβ deposition from the human
brain is still missing.
We speculated that BACE1 elevation could occur at
sites of amyloid angiopathy in the human brain. As such,
identifying the cellular elements showing increased
BACE1 expression could help reveal the origin of patho-
logically important Aβ products in the development of
CAA. In the present study we choose a cohort of post-
mortem brains from our recently established human
brain banks [32]. BACE1 alteration relative to Aβ and
other labeling was determined anatomically and bio-
chemically, with a focus on cerebral vascular and lepto-
meningeal lesions. For cross-validation, neuritic plaques
were examined and documented as a reference system
when appropriate. Primary cell cultures were also used
to verify the existence of the amyloidogenic machinery
in vascular and meningeal cells.
Methods
Postmortem human brains and surgical biopsies
Postmortem human brains were obtained through the
Willed Body Donation Programs at Peking Union Medical
College and Xiangya School of Medicine. Surgical hu-
man biopsies were obtained from the Departments of
Neurosurgery, Otolaryngology-Head and Neck Surgery of
the Affiliated Tumor Hospital of Central South University
following informed consent. All experimental procedures
were approved by the Institutional Ethics Committee for
Research and Education.Brains were from donors who were not clinically diag-
nosed with dementia of the AD or vascular type at the
time of hospitalization for the care of terminal illnesses.
Amyloid and tau pathology were evaluated in sections
from the prefrontal and temporal lobe blocks to identify
proper samples for the present study. A total of 30 cases
were selected and matched into a group with brain
amyloid pathology (i.e., parenchymal and vascular amyl-
oid deposition) and a control group that showed no Aβ
deposition in the brain, with the amyloid and neuro-
fibrillary lesions scored according to the Braak staging
method [33,34] (Table 1). Given a mixed presence of
parenchymal and vascular amyloid pathology in individual
cases, the former group was referred to as the “amyloidosis”
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between the two groups. Tau pathology existed in the ma-
jority of the “amyloidosis” cases as well as a few control
cases (Table 1).
Brain tissue processing
The brains were bisected after removal, with each hemi-
sphere further cut at the frontal plane into approxi-
mately 2 cm-thick slices. The slices from one half-brain
were fixed by immersion in 4% paraformaldehyde in
0.1 M phosphate-buffered saline (PBS) for 4 days at 4°C,
with the slices of the other half-brain stored at -70°C. A
prefrontal (~6 cm from the frontal pole) and two temporal
slices (passing the amygdala and mid-hippocampus) were
taken from the fixed half-brains, and then placed in 10-
30% sucrose in 0.01 M phosphate buffer for cryoprotec-
tion. These brain blocks were cut at the frontal plane into
sections at 40 μm-thickness in a cryostat. For each block,
twelve sets of sections were collected into 6-well culture
plates, with each set containing 10 sections with equal in-
tervals (~500 μm apart). Sections were washed with PBS
for 3 times to remove the embedding medium before they
were transferred into a cryoprotectant and stored at -20°C
until histological studies.
Preparation of postmortem leptomeningeal samples
Leptomeninge over the temporal lobes was peeled off
with a pair of fine forceps after brain removal, and
rinsed thoroughly in cold PBS. Meningeal blood vessels
identifiable under the dissection microscope were dis-
sected out and collected separately. For each case, the
leptomeningeal vascular and the relatively “pure” menin-
geal samples were divided into two parts, with the first
fixed in 4% paraformaldehyde overnight then processed
histologically as described above for the brain samples,
except that the sections were cut at 20 μm in thickness
and thaw-mounted on microslides. The remaining sam-
ples were stored frozen (-70°C) until being used for bio-
chemical assays.
Preparation of peripheral human vascular biopsies
Small arteries and veins ranging 0.5-2 mm in diameter
were obtained at surgery from patients (n = 8, males,
37-60 year-old) suffering from benign thyroid lesions. Ves-
sels were isolated from subcutaneous or intermuscular
fascia before exposure and resection of the thyroid tissue.
A small part of peripheral vascular biopsy was fixed in 4%
formaldehyde, and used for histological examination. The
remaining part was collected in ice-old Dulbecco’s modi-
fied Eagle’s medium with Nutrient Mixture F12 (DMEM/
F12; Life Technologies Corporation, Shanghai, China),
and used for biochemical (n = 4) and primary cell culture
(n = 4) studies.Preparation of leptomeningeal biopsies
Leptomeningeal biopsies were obtained at surgery from
six patients suffering from deep brain glioma (males; 47-
63 year-old). The leptomeninge over the cortex to be
resected was peeled off under surgical microscope, before
the underlying cortical tissue was aspirated. The lepto-
meningeal samples were collected in ice-old Dulbecco’s
modified Eagle’s medium with Nutrient Mixture F12
(DMEM/F12; Life Technologies Corporation, Shanghai,
China), and used primarily for primary cell culture, with a
few arterioles dissected out in each case for anatomical
study as well.
Primary vascular and meningeal cell culture
Resected small arteries and leptomeninge samples were
digested in 0.25% Trypsin-EDTA solution (Catalog
#25200-072; Life Technologies Corporation) and centri-
fuged at 15,000 g for 10 minutes. The resulting cell pellets
were re-suspended with DMEM/F12 containing 10% fetal
bovine serum, adjusted to a beginning cell density ap-
proximately 5 × 106 cells/mL. Cells were cultured at 37°C
in a humidified atmosphere containing 95% air and 5%
CO2, in Corning-Costar plates (Catalog #CLS3516; Life
Technologies Corporation). Each well was loaded with
2 ml of medium and a glass coverslip coated with polyly-
sine, with the medium changed every 2 days.
Primary antibodies
A set of well-characterized primary antibodies were used in
the present study for immunohistochemistry and immu-
noblot (Table 2). These included antibodies for profiling
AD-type neuropathology (Aβ, APP, BACE1, phosphorylated-
tau), determination of neuronal (MAP2, β-tubulin, synap-
tophysin), vascular (collagen-IV), endothelial (CD31) and
smooth muscle components (smooth muscle actin, αSMA),
as well as reference proteins (β-actin and GAPDH).
Immunohistochemistry and immunocytochemistry
Sections from multiple cases were stained histologically
and immunohistochemically under identical conditions
in each experiment. Antigen retrieval was applied for
BACE1 labeling, with 50% formamide and 50% 2 × SSC
(0.3 M sodium chloride and 0.03 M sodium citrate) at
65°C for 1 hour; and for Aβ antibody labeling, with 50%
formic acid in PBS for 30 minutes at room temperature.
Immunostaining with the ABC method began with a
treatment of sections in 5% H2O2 in PBS for 30 minutes,
followed by a pre-incubation in 5% normal horse serum
in PBS with 0.3% Triton X-100 for 1 hour. Incubations
with the primary antibodies were carried out at 4°C
overnight with gentle agitation, after which sections
were reacted with a biotinylated pan-specific secondary
antibody (horse anti-mouse, rabbit and goat IgGs) at
1:400 for 2 hours. Following reaction with the ABC
Table 2 Primary antibodies used in the present study
Antibody Source Product # Dilution
Mouse anti-Aβ1-42, 12 F4 Signet 39240 (1:2000)
Mouse anti-Aβ1-16, 6E10 Signet 39320 (1:4000)


















Mouse anti-CD31 Dako M0823 (1:1000)
Mouse anti-collagen, type IV Sigma-Aldrich C1926 (1:1000)

















Mouse anti-synaptophysin (SYN) Millipore MAB329 (1:4000)
Rabbit anti-β-tubulin-III Sigma-Aldrich T2200 (1:10000)
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USA) for 1 hour, immunoreactivity was developed in
0.003% H2O2 and 0.05% 3,3’-diaminobenzidine (DAB).
Brain sections were washed 3 times, 10-minute each,
between antibody incubations.
Double immunofluorescence was initiated with an incu-
bation of the sections in PBS containing 5% donkey serum
for 30 minutes, followed by reaction with a pair of primary
antibodies raised in different species (Table 2) overnight at
4°C. On the second day, sections were incubated at room
temperature for 2 hours with Alexa Fluor® 488 and Alexa
Fluor® 594 conjugated donkey anti-mouse, anti-rabbit or
anti-goat IgGs (1:200, Invitrogen, Carlsbad, CA, USA).
Sections were further treated with the autofluores-
cence eliminator (Catalog #2160, Millipore, Billerica,
USA), counter-stained with bisbenzimide (Hoechst 33342,
1:50000, Catalog #B2261, Sigma-Aldrich) and mounted
with anti-fading medium. For immunocytochemistry, cells
grown on glass coverslips were fixed with 4% paraformal-
dehyde for 30 minutes. Single or double immunofluores-
cence was carried out on-slide to determine the expressionof amyloidogenic and specific vascular cell proteins using
the protocols described above for brain tissue staining.
Histology and histochemistry
Some immunolabeled sections were counterstained with
toluidine blue or cresyl violet to facilitate histological
orientation or graphic illustration. A few BACE1/Aβ anti-
body immunostained sections from each case were further
processed with Perl’s Prussian blue stain to visualize ferric
iron leakage/deposition. In addition, at least two temporal
lobe sections from each brain were initially processed for
nicotinamide adenine dinucleotide phosphate diaphorase
(NADPH-d) histochemistry. Sections showing optimal
neuronal NADPH-d reactivity were dual-stained for
BACE1 and Aβ [35,36].
Western blot
Postmortem leptomeningeal samples, vascular biopsies and
cultured cells were homogenized by sonication in T-PER
extraction buffer (Pierce, Rockford, IL, USA) containing
protease inhibitors (Roche, Indianapolis, IN, USA). The
lysates were centrifuged at 15,000 g, with supernatants
collected and protein concentrations determined by DC
protein assay (Bio-Rad Laboratories, Hercules, CA, USA).
Extracts containing 50 μg protein were run in 8%, 14% or
20% SDS-polyacrylamide gel electrophoresis (PAGE) gels.
Separated proteins were electrotransferred to Trans-Blot
pure nitrocellulose membranes (Bio-Rad Lab.). The nitro-
cellulose membrane strips containing the target proteins
were immunoblotted with antibodies to APP (22C11),
APP β-CTF or C99 (AHP538, 6E10), BACE1, PS1-NTF
(ab14), β-tubulin-III, β-actin or glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). The membranes were further
reacted with HRP-conjugated goat anti-rabbit or anti-
mouse IgGs (1:20000; Bio-Rad Laboratories), with pro-
tein signal visualized with the ECL-Plus Western Blotting
Detection Kit.
APP β-site cleavage (BACE1) activity assay
Activities of β-site APP cleavage in tissue/cell lysates
were measured in duplicate in 96-well transparent flat-
bottomed plates. Samples were homogenized on ice as
described above for western blot analysis, and assayed
for enzyme activity using a commercial kit (Calbiochem,
La Jolla, CA, USA, Catalog #565785), following the
manufacturer’s instructions. The fluorescent signal was
captured in a Bio-Rad microplate reader (PR 3100 TSC).
Enzyme linked immunosorbent assay for Aβ
Aβ42 levels (pM/ml) in leptomeningeal lysates were
assayed in duplicate by solid sandwich enzyme-linked
immunosorbent assay (ELISA) using a commercial kit
(Novex®KHB3442 for Aβ42) following the manufacturer’s
instruction (Life Technologies Corporation). Signals were
Xue et al. BMC Neurology  (2015) 15:71 Page 5 of 15captured in the Bio-Rad microplate reader (PR 3100 TSC).
Aβ concentrations were calculated according to the stan-
dard curve generated from the readouts of synthetic
peptides.
Imaging, data analysis and figure preparation
Sections were examined on an Olympus fluorescent
BX53 microscope equipped with a digital imaging sys-
tem (CellSens Standard, Olympus Corporation, Japan), and
on a confocal microscope (Nikon-EZ-C1, Japan). Confocal
images were processed with the Nikon-EZ-C1 Viewer soft-
ware. Images were taken using 2× to 40× objectives, with
low magnification images montaged for presentation. All
confocal immunofluorescence images were taken with the
20 × objective by three scanning of tissue with each in a
depth of 1.9 μm. Images prepared for densitometric ana-
lysis were obtained at once following a single batch of im-
munohistochemical preparation, with the same exposure
setting applied for all photo documentation. A correlated
densitometry was designed for comparing BACE1, 6E10
and bisbenzimide labeling at individual intracortical vascu-
lar profiles in (the methodology will be detailed later with
illustration). Optic densities of protein bands were obtained
on immunoblot images, with the data normalized to the
internal references.
Densitometric and numerical data were processed for
group comparison by calculation of means and standard
derivations (SD), with normalization to appropriate re-
ference applied. Statistical comparison of means were
performed using Student-t test, or one-way ANOVA
with posthoc test (Prism GraphPad, San Diego, CA,
USA), with the minimal significant level of difference set
at p < 0.05. Figures were assembled with Photoshop 7.0.
Results
Identification and morphological characterization of
vascular BACE1 labeling
Increased BACE1 immunoreactivity (IR) relative to par-
enchymal amyloid pathology has been reported in ani-
mal and human brains [32,35,36]. Consisted with the
existing data, increased BACE1 and Aβ IR were found in
the cases with brain amyloid pathology as compared to
controls (Figure 1). Briefly, in the cases of the amyloid-
osis group, BACE1 IR was increased at local sites against
an overall neuropil-like background (Figure 1A,B,D,E).
In contrast, BACE1 IR in control cases exhibited essen-
tially a diffuse neuropil-like pattern across the temporal
lobe cortical structures (Figure 1C,F). The distinct BACE1
labeling normally present at the mossy fiber terminal field
was otherwise comparable between cases with and with-
out cerebral amyloid pathology (Figure 1A-C).
Importantly, while essentially no vascular BACE1
IR was identifiable in sections from the control group
(Figure 1C,G,H), increased BACE1 IR was seen at somevascular profiles in the cortex and hippocampal formation
in the cases with neuritic amyloid pathology (Figure 1B,E,I,J).
In general, the increased vascular BACE1 IR could occur
around the pia (will be detailed in following section), in
any cortical layer or in the white matter. The labeled ves-
sels varied in size, but appeared to be mostly capillaries
and arterioles as judged on the basis of their size, histo-
logical configuration and laminar distribution. This site-
specific increase of BACE1 IR at capillary and arteriole-like
profiles was confirmed by double immunofluorescence
for BACE1/6E10 (Figure 1K-N) and BACE1/collagen IV
(Figure 2A, B). At higher magnifications, BACE1 IR at
blood vessels exhibited variable patterns and intensities in
DAB (Figure 2C,D) or DAB/H.E. dual-stain (Figure 2E-H)
preparations, better appreciated in the latter wherein the
vascular lamination was displayed. Specially, BACE1 IR at
arteriole-like profiles showed a differential laminar distri-
bution that was related to the overall amount of labeling
at individual vessels. Thus, when comparing intracortical
arterioles without (Figure 2E) to those with BACE1 IR
(as assessed in the same sections), the labeling appeared to
occur initially then intensify in the tunica intima (TI) or
endothelial layer (Figure 2F). As the endothelial BACE1 IR
became evident, labeled elements often occurred in the
perivascular area, with the tunica media (TM) or the
smooth muscle layer spared (Figure 2C). As the overall
BACE1 IR became more abundant, the labeling occurred
also in the TM (Figure 2G,H). BACE1 IR in and surround-
ing the vascular wall might appear segmentally along the
vessels cut longitudinally, giving the profile a feather-like
appearance (Figure 2D). It should be noted that BACE1
labeled elements in the (TM) appeared as fine processes,
some had local swellings (Figure 2G,H), suggestive of a la-
beling to neuronal terminals than smooth muscle cells.
The vascular Aβ IR exhibited a differential labeling
pattern in ABC-DAB immunohistochemical prepara-
tions. As defined by some neuropathologists [13], vas-
cular Aβ deposition could be staged according to the
pattern and amount of Aβ IR between individual vessels,
which was applicable to the intracerebral arterioles exhi-
biting 6E10 IR in this study (Figure 2I-M). Thus, light
6E10 IR appeared to initially occur at the TI or endothe-
lial layer (Figure 2I), followed by the emergence and in-
tensification of the labeling in the TM (Figure 2J-L).
However, we observed perivascular 6E10 IR at arterioles
with fairly light or heavy Aβ IR in the vascular wall
(Figure 2J-K). The profiles containing vascular and pe-
rivascular Aβ IR resembled the so-called “dysphoric or
dyshoric CAA” defined in previous studies [13,37,38].
Correlative analysis of vascular BACE1 and Aβ antibody
labeling
In double immunofluorescence, a distinct endothelial
BACE1/6E10 colabeling was identified at intracerebral
Figure 1 Representative images showing increased β-secretase (BACE1) immunoreactivity (IR) at selected vascular sites, in addition to neuritic
plaques, in the human brains with amyloid deposition relative to controls. Panels (A-F) are montages of low magnification images showing BACE1
(A-C) and 6E10 [reactive to Aβ, potentially to β-amyloid precursor protein (APP) and APP β-C-terminal as well] (D-F) IR over the subiculum (Sub),
hippocampus (CA sectors) and dentate gyrus (DG) between adjacent sections from two cases with brain amyloid pathology (A,B,D,E) and one control
(C,F). In the second case (B,E), vascular BACE1 and 6E10 labeling (arrows) is evident at low magnification. In the control case, no staining is seen with
6E10 labeling (F, with tissue lamination illustrated by toluidine counterstain). Note that the BACE1 IR at the mossy fiber terminal field is comparable in
(A-C). Panels (G-J) show low magnification views of BACE1 IR in the temporal neocortical grey and white matter from two additional brains, with a
diffuse neuropil pattern in the control (G,H) and increased labeling in the amyloid case at selected vascular profiles (I.J). Confocal double immunofluorescence
shows a partial colocalization of BACE1/6E10 IR among typical neuritic plaques (K-N), with the structures exhibiting overlapped labeling (appearing
yellow) representing dystrophic neurites (M,N). A capillary profile exhibiting weak BACE1/6E10 IR is also seen in the field (M, N). Scale bar in (A)= 2.5 mm,
applying to (B-F), equivalent to 500 μm for (G-J), 200 μm for (K-M) and 50 μm for (N).
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arranged as a ring-like pattern in the absence of BACE1
IR (Figure 3A-C). Among the intracortical arterioles dis-
playing BACE1/6E10 IR in the middle wall, a pattern of
partial colocalization was recognized (Figure 3D-F). At
some intracortical vessels with heavy 6E10 IR, the inten-
sity of BACE1 IR was otherwise at the background levels
(Figure 3G-I). As a reference, typical neuritic plaques
showed a partial colocalization pattern as well, with
BACE1/6E10 IR overlapped only in the dystrophicneurites that were surrounded by 6E10 reactive Aβ de-
posits (Figure 3G-I). The differential colocalization of
BACE1 relative to intracellular vs. extracellular 6E10 IR
might be related to a cross-reactivity of 6E10 to intra-
neuronal APP and/or APP β-C terminal fragments, al-
though the 6E10 IR inside the dystrophic neurites could
reflect the existence of intracellular Aβ [25].
In ABC-DAB immunohistochemical preparations, cell
loss was readily noticeable in the wall of the intracortical
arterioles with relatively strong BACE1 IR (compare
Figure 2 Morphological characterization of vascular (arteriolar) BACE1 and 6E10 immunoreactivity (IR) in postmortem human temporal neocortex.
Panels (A,B) show selective BACE1 labeling at cortical vasculature visualized by collagen IV. Panels (C) illustrates BACE1 IR at a cross-sectioned
arteriole, localizing to the tunica interna (TI) and around the tunica adventitia (TA) or the perivascular area, but not in the tunica media (TM).
Panel (D) shows a feather-like pattern of BACE1 IR along a longitudinally cut intracortical arteriole. Panels (E-H) illustrate variable patterns of BACE1 IR
among labeled (F-H) relative to unlabeled (E) arterioles in immunohistochemical preparation with hematoxylin and eosin stain (H.E.) counterstain.
Arrows points to BACE1 IR in the TI (C,F), TA (C,D) and TM (G,H). Loss of cells in the vascular wall is noticeable in (G) and (H) relative to (E) and (F).
The BACE1 IR in the TA and TM appears process-like (C,D,G,H). Panels (I-L) illustrate variable patterns of Aβ labeling at arterioles, with Aβ IR occurs
primarily at the TI (I) or in the TM (J-L). Perivascular Aβ IR (arrows) often co-exists among the profiles with Aβ deposition in the TM with varying
intensity (J-L), and appears segmentally in longitudinal view of the labeled vessel (M). Scale bar = 500 μm in (A) applying for (B); equal to 200 μm
for (M) and 100 μm for other panels.
Xue et al. BMC Neurology  (2015) 15:71 Page 7 of 15Figure 2G,H to E,F). We also noticed a loss of bisbenzi-
mide labeled nuclei in the vascular wall of vessels with
moderate to strong BACE1/6E10 IR in double immuno-
fluorescence. In order to assess whether there existed a
trend of relative changes in BACE1 IR, 6E10 IR and cell
loss, we carried out correlative densitometry for the 3
variables among individual cortical and white matter
arterioles. This was conducted in batch-processed im-
munofluorescent sections from 5 cases. While scanning
over the cortex and white matter (following an alterna-
ting path), each 6E10 labeled arterioles encountered was
imaged. A set of images [the red (BACE1), green (6E10)
and blue (bisbenzimide) channel] from the same brain
was then put together, converted into a black and white
tiff file. Using the OptiQuant software, a measuring tem-
plate was created in the original green image over the
area occupied by 6E10 IR at the blood vessel. This same
template was copied and pasted over the other twoimages and aligning to the same vessel (see Figure 3D/E
and G/H for methodological illustration). The optic den-
sities for the 3 types of labeling at the same vascular
profile were thus obtained. For a given brain, 20 cross-
sectioned intracerebral arteriolar profiles were analyzed
by this method. To obtain the baseline densities, 10
cross-sectioned intracortical arterioles not labeled by
BACE1 and 6E10 encountered in the same microscopic
fields were also photographically documented in each
brain. The “immunofluorescent” (actually the background)
and bisbenzimide densities were obtained by the same
method, except that the vascular measuring template was
created in the bisbenzimide image (for a methodological
demonstration see the framed artery in Figure 4A).
Among a total of 100 quantified amyloid arterioles,
the mean optic densities were 4397.9 ± 298.4 DLU/mm2
for BACE1 IR, 6328.6 ± 794.9 DLU/mm2 for 6E10 IR and
222.5 ± 11.9 DLU/mm2 for bisbenzimide fluorescence. For
Figure 3 Correlative morphometric characterization of BACE1 and 6E10 immunoreactivity (IR) in intracortical arterioles in confocal fluorescent
preparation. Panels (A-C) show colocalized BACE1/6E10 IR in the endothelia (arrows), with a ring-like Aβ deposition (arrowhead) in the smooth
muscle layer that is not colocalized with BACE1 IR. Panels (D-F) demonstrate an arteriole containing BACE1 labeled neurites and local Aβ deposition
(arrowheads) in the vascular wall, with BACE1 IR colocalizing with 6E10 IR inside but not outside swollen process-like elements (arrows). Panels (H-J)
show a vessel with densely packed Aβ products in the wall, with BACE1 IR over the same area comparable to background. Fusiform bisbenzimide
(Bis)-labeled nuclei appear lost in the middle layer of arterioles in (D/E, G/H) relative to (A/B). A typical neuritic plaque (NP) consisted of BACE1 labeled
dystrophic neurites and Aβ deposits is also seen in (G-I). Panels (J) plots the mean optic densities (o.d.) of BACE1, 6E10 and bisbenzimide fluorescence
measured over the wall of individual normal [i.e., amyloid negative (-), 10/brain)] and amyloid [i.e., amyloid positive (+), 20/brain] arterioles from five
individual brains, with the area of interest (AOI) illustrated as the purple-line circled areas in (D/E and G/H, and also in Figure 4A to demonstrate the
method to measure densities at normal control vessels). Note the increase of BACE1/6E10 o.d. and reduction of bisbenzimide o.d. in the amyloid (+)
relative to (-) arterioles. Panel (K) shows a correlative densitometric analysis by sorting the order of individual vessels (n = 100 from 5 brains) according
to their elevated levels of 6E10 densities relative to baseline (defined as 100%, mean of densities reported from all non-amyloid vessels). BACE1 density
increases initially in parallel with that of 6E10 IR, but tends to reduce among most profiles as 6E10 IR further increases. Bisbenzimide density tends to
decline with the increase of 6E10 labeling. Scale bar = 50 μm in (A) applying to (B,C,G-I), equivalent to 100 μm for (D-F).
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same 5 brains), the mean densities were 3298.3 ± 268.5,
3317.1 ± 237.0 and 253.4 ± 41.3 DLU/mm2 for BACE1,
6E10 and bisbenzimide signals, respectively (Figure 3J).
There was a significant difference between the amyloid
and control arterioles for the mean density of BACE1 IR
(P < 0.0001), 6E10 IR (P = 0.0003) and bisbenzimide
(P = 0.0001) (two-tailed Student-t test). To explore a trendof change between the 3 variables, the density of each
marker measured at a given vessel was normalized to the
mean density of the corresponding marker from all con-
trol profiles (i.e., defined as 100% or baseline). The order
of the vascular profiles was then resorted according to the
normalized 6E10 densities (from low to high), with the 3
variables plotted as a function of the vascular order num-
bers (Figure 3K). BACE1 and 6E10 IR concurrently
Figure 4 Neuritic profiles inside and surrounding the wall of intracerebral arterioles from cases with brain amyloid pathology. Panels (A-C) show
a partial colocalization of BACE1 and synaptophysin immunofluorescence in the vascular wall of an arteriole in the subcortical white matter (WM)
(arrows pointing to colocalized parts), with a nearby arteriole (circled with broken purple line) exhibited background signal for both markers.
Panels (D) shows BACE1 labeled dystrophic neurites (arrows) partially colabeled (enlarged insert) for nicotinamide adenine dinucleotide phosphate
diaphorase (NADPH-d) surrounding an intracortical vessel, with clusters of dystrophic neurites (DN) in the field. Panel (E) shows NADPH-d positive
dystrophic neurites (arrows) in and around the wall of a vessel with Aβ deposits. Panel (F) shows rosette-like NADPH-d positive dystrophic neurites in
compact amyloid plaques (NP). Panels (G,H) show BACE1 labeled neurites in small (G) and larger (H) amounts in the vascular wall that are partially
colabeled by Prussian blue, as are those organized as rosset-like clusters (I). The colabeled parts appear grey to black because of the brown DAB
background color. The AOI label in (A) illustrates a method to measure optic density in normal arterioles (referring to Figure 3K-L). Scale bar = 100 μm
in (A) applying to (B-I).
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proximately at a plateau as the levels of 6E10 IR continued
to rise until about 2 fold of the baseline. While 6E10 IR in-
creased further up to 4 fold of the baseline density, BACE1
IR did not continue to elevate but tended to drop towards
the baseline among many profiles. Bisbenzimide density
tended to decrease with the increase in 6E10 IR, especially
among the vascular profiles with 6E10 density reached
and above 2 fold of the baseline level (Figure 3K).
Cross-validation of abnormal neurites inside and
apposing to vascular wall
The aforementioned BACE1 immunoreactive elements in
the perivascular area and TM were of particular interest
as they could imply other cellular contributors than the
endothelial cells (verifiable simply by regular histology) of
Aβ to amyloidosis. Using double immunofluorescence, the
process-like BACE1 immunoreactive elements were found
to partially colocalize with synaptophysin (Figure 4A-C).These elements were not labeled with αSMA, a marker of
vascular smooth muscle cells (data not shown). The in-
complete BACE1/synaptophysin colocalization was consi-
dered to indicate that BACE1 elevation was not limited to
(dystrophic) presynaptic terminals. As a cross-validation
for this latter possibility, we used another neuronal marker,
NADPH-d, which could display neuronal processes exten-
sively [39-41]. Following an initial histochemical screening,
cases with optimal neuronal NADPH-d reactivity were
subjected to further BACE1 and 6E10 immunolabeling.
NADPH-d reactive dystrophic neurites were observed in
the vascular wall or the perivascular zone, coexisting with
BACE1 (Figure 4D) or in mix with local Aβ deposition
(Figure 4E). NADPH-d reactive dystrophic neurites were
also present in some amyloid plaques (Figure 4F).
Considering the well-established link between CAA and
microbleeding [10-12], we explored whether vascular
profiles with BACE1 labeled neurites might be associated
with hemosiderin leakage. In sections counterstained with
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as well as at perivascular area among the arterioles with
BACE1 labeled neuritic profiles (Figure 4G-I). There were
BACE1 immunoreactive neurites directly colabeled by
Prussian blue, with some extended to near the vascular
cavity, even in arterioles with a small amount of dys-
trophic neurites (Figure 4G,H). Iron deposition was also
seen at subset of BACE1 labeled dystrophic neurites
arranged as rosette-like clusters (Figure 4I), which would
represent the sites of parenchymal neuritic plagues.
Characterization of amyloidogenic protein expression in
vascular biopsy and cultured cells
As with previous animal and human brain studies
[35,36,42,43], BACE1 IR was essentially not detectable at
cerebral vasculature in brain sections from the control
cases or at normal vessels in brain sections with amyloid
pathology. This would appear not surprising in general
given that the differentiation of specific immunolabeling
depends on a sufficient signal to background ratio. In
other words, since BACE1 is more abundantly expressed
in neuronal than vascular elements, neuronal BACE1 IR
could mask vascular BACE1 IR, if any, in brain sections
under normal conditions. Because “de novo” BACE1 IR
was identified at selected vascular sites in postmortem
human brain in the present study, we speculated that
vascular cells should express BACE1 and perhaps other
Aβ producing proteins endogenously.
Surgically isolated blood vessels and primary cell cul-
ture, together with human cortical extracts as control,
were used to explore the expression of amyloidogenic
proteins in adult human vascular cells. In biopsied lepto-
meningeal and peripheral (image not shown) arteriolar,
venular (image not shown) and capillary preparations,
BACE1, APP and PS1 (not shown) IR were detectable by
immunohistochemistry, localized largely to the endothe-
lial cells (Figure 5A-C). It should be noted that, in rela-
tively large arteries [i.e. with an internal elastic lamina
(IEL)], strong and weak fluorescent signal existed in the
IEL and TM, respectively (Figure 5B,C). By excluding the
primary (Figure 5D,E) or secondary (image not shown)
antibodies, the endothelial BACE1 and APP IR became
eliminated, while the fluorescent signal in the IEL and TM
largely remained, as compared with that in the normally
processed sections (Figure 5B,C, inserts). Thus, the fluores-
cent signal in the endothelial layer appeared to be specific,
whereas that in IEL and TM was largely autofluorescence.
Protein products of APP, BACE1 and APP C-terminal
fragments were detected in the extracts of the leptome-
ningeal and peripheral vascular biopsies, at lower levels
relative to the cortex (Figure 5F). Notably, vascular APP
holo-proteins migrated at a slightly heavier molecular
weight position relative to brain APP. Presenilin-1
N-terminal fragments (PS1-NTF), an active componentof γ-secretase complex, were also detected in vascular
lysates, although at similar levels between the cortical,
arterial and venous samples. The vascular samples showed
an expected minimal amount of the β-tubulin proteins as
compared to cortical lysates (Figure 5F). Vascular extracts
were also found to exhibit APP β-site cleavage enzymatic
activity, and contain detectable amounts of Aβ42 (data
not shown). Immunocytochemical characterization on the
expression of amyloidogenic proteins was carried out in
primary cell cultures of resected peripheral arteriolar sam-
ples maintained in vitro for 4-8 days. Cells expressing
CD31, a marker of the endothelia, were found to co-
express APP, BACE1 and PS1-NTF IR (Figure 5G-L). Cells
expressing the smooth muscle actin ∀SMA, including
some appearing in a fused configuration, exhibited mini-
mal BACE1 IR (Figure 5M,N).
Characterization of BACE1 elevation in association with
leptomeningeal amyloidosis
In addition to the above findings, we observed increased
BACE1 IR on the pial surface in a subset of cases with
parenchymal and vascular amyloid pathology (Figure 6).
Specifically, increased BACE1 IR around the pia was dis-
tinct in sections from 5 cases of the group with prominent
intracortical CAA (Figure 6A), whereas BACE1 IR at the
same location was minimal in control cases (Figure 6C).
Individual BACE1 immunoreactive cells in round or oval
shape localized along the pia, apparently lacking processes
typical of neuronal or glial cells (inserts in Figure 6A). In
adjacent sections, amyloid deposition was present on the
cortical surface and also in nearby vascular profiles in
these same cases, in contrast to controls (Figure 6B,D).
The finding of concurrent increases of BACE1 and Aβ
IR along the pia allowed an opportunity for biochemical
verification of the protein change using isolated lepto-
meningeal samples (Figure 6E,F). Extracts of the lepto-
meningeal samples over the temporal neocortex of the
anatomically verified amyloid and control cases were
assayed (Figure 6G-I). BACE1 protein levels were elevated
in the lysates of the amyloidosis group (134.2 ± 19.2% of
GADPH levels, mean ± SD) relative to control (95.0 ±
11.1%) (P = 0.021, n = 5, Paired t test, same test below)
(Figure 6G,H). APP β-cleavage activity was increased in
the amyloidosis cases (174.9 ± 35.5%) relative to controls
(100 ± 16.9%) (P = 0.001) (Figure 6H). Levels of APP C99
were also higher in the amyloidosis group (103.2 ± 32.3%
of GADPH levels) than control (70.9 ± 18.3%) (P = 0.009)
(Figure 6G,H). Moreover, Aβ42 levels were elevated for
about 2 fold in the amyloidosis cases (221.6 ± 86.2 pM/ml)
compared to controls (63.2 ± 8.1 pM/ml) (P = 0.013)
(Figure 6I).
Immunocytochemistry was used to determine if BACE1
and other Aβ producing proteins could be endogenously
expressed in meningeal cells. Meningeal biopsies (from 6
Figure 5 Characterization of the expression of amyloidogenic proteins in vascular biopsy and primary vascular cell culture. Panels (A-E) show the
expression of the β-amyloid precursor protein (APP) and BACE1 in leptomeningeal biopsy containing a middle-sized and several small arteries
(arrow), and capillaries. The endothelial cells (E→) expressed specific APP and BACE1 immunoreactivity (B,C), which can be eliminated by excluding
the primary antibodies (1st AB) in immunofluorescent processing (D,E). Autofluorescence exists in the inner elastic lamina (IEL), tunica media (TM) and
external elastic lamina (EEL) (refer to the H.E. stained inset in A). Panel (F) shows immunoblot characterization of the amyloidogenic proteins in extracts
of isolated leptomeningeal arteries, peripheral arteries and veins, with cortical extract (from a control case) used as assay control (50 μg protein loading
in each lane). APP, BACE1, presenilin-1 N-terminal fragments (PS1-NTF) and APP β-cleavage products are present in the vascular homogenates. Note
that the vascular APP migrates at a higher molecular weight position relative to the brain counterpart. The vascular samples contain minimal amount
of β-tubulin relative to cortical lysate. Panels (G-L) illustrate immunocytochemical labeling of APP, BACE1 and PS1-NTF in cultured vascular cells
expressing CD31, a marker for vascular endothelia. A large cellular profile (appeared as fused cells) is labeled with the smooth muscle cell marker,
α-smooth muscle actin (αSMA), but exhibits little BACE1 immunoreactivity (M,N). Scale bar = 500 μm in (A) applying to (B,C); equal to 250 μm for
(H-I) and 50 μm for (E-G).
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this question. In initial assays the cultured cells derived
from 3 cases showed 70-90% purity of human menin-
geal cells, as characterized by a polygonal morphology
(Figure JE) and the expression of fibronectin (FN), and a
lack of labeling for GFAP (astrocytic marker), CD11
(endothelial marker) or MAP2 (neuronal marker) [44].
We then carried out double immunofluorescence to check
the expression of amyloidogenic protein. These experi-
ments revealed BACE1 (Figure 6K,L), APP (Figure 6M)
and PS1 (data not shown) labeling in the meninge-
derived cells.Discussion
BACE1 elevation in vascular endothelia and perivascular
neurites in CAA
Several previous studies have reported that vascular
endothelia are capable of producing Aβ in vitro, as cha-
racterized with the brain microvascular endothelial cell
(BMEC) and the human umbilical vein endothelial cell
(HUVEC) lines [27-29]. Notably, vascular endothelial
cells express the three alternatively spliced APP mRNA
isoforms APP695, APP751 and APP770, whereas neu-
rons express APP695. At the protein level, APP770 is
the major variant expressed by the vascular endothelial
Figure 6 Characterization of BACE1 elevation in meningeal cells associated with leptomeningeal amyloidosis. Panel (A) shows BACE1 labeled
cells aligning along the pia mater in a case with cerebral amyloid angiopathy with prominent leptomeningeal amyloidosis (B), in contrast to a
control case wherein no BACE1 and Aβ (6E10) labeling is present at the pia (C,D). Arrows in (A,B) points to profiles with increased BACE1 and
6E10 IR over the background. Panel (E) shows a preparation of leptomeninge sample from the temporal lobe (E), which are rinsed thoroughly in
cold phosphate buffer for biochemical analysis (F). Levels of BACE1 protein and C99 in leptomeningeal lysates are elevated in 5 cases with CAA
relative to 5 control cases (G,H), as is BACE1 enzymatic activity measured in the lysates (H). Aβ42 levels are also higher in the CAA group relative
to control (H). In primary cell culture of leptomeningeal biopsies, meningeal cells appear polygonal under phase contrast microscope (J), co-express
fibronectin (FN) (K) and BACE1 (L). These cells also express the β-amyloid precursor protein (APP) (H, the corresponding FN labeling image is
not shown). Scale bar = 250 μm in (A) applying to (B-D), equivalent to 50 μm for inserts in (A,B), 25 μm for (J) and 12.5 μm for (K-M).
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identified to exhibit increased BACE1 IR in postmortem
human brains with cerebral amyloidosis, as compared to
controls. Immunocytochemical and biochemical analyses
indicate the presence of the amyloidogenic proteins in
vascular cells, with BACE1 being detected in endothelial
but not smooth muscle cells. Vascular APP migrates at a
slightly heavier position than the brain counterpart in
immunoblot, consistent with the notion that the formerlikely represents the APP770 variant [45]. APP β-CTF
and APP β-cleavage enzyme activity are detectable in
vascular biopsies and primary cells.
We also demonstrate here novel BACE1 immunoreac-
tive neuritic elements in the perivascular region in aged
human brains with CAA, which may extend into the para-
vascular parenchyma as well as into the vascular wall. The
neuritic nature of these elements is indicated by their
sprouting/swelling configuration and colocalization with
Xue et al. BMC Neurology  (2015) 15:71 Page 13 of 15synaptophysin. In line with the BACE1 data, sprouting/
dystrophic neurites within and outside the vascular wall
are visualized by NADPH-d histochemistry, which labels
neuronal processes innervating vasculature in the normal
mammalian cerebrum [39-41]. These findings demonstrate
that neuritic elements present around cerebral vasculature
under physiological conditions could develop into amyloi-
dogenic dystrophic neurites with a potential to sprout into
the vascular wall under pathological conditions.
The BACE1 labeled neuritic elements appear to de-
velop in the smooth muscle layer after the afore-
mentioned endothelial BACE1 elevation. The correlative
morphometric analysis further suggests that the occur-
rence of these abnormal neurites in the vascular wall is
associated with an increasing Aβ deposition and loss of
cells (bisbenzimide nuclear profiles) in the vascular wall.
In line with the fact that CAA is commonly associated
with microbleeding [5-14], we also find iron deposition
at sites with BACE1 labeled dystrophic neurites inside
and surrounding the vascular wall.
BACE1 elevation in meningeal cells associated with
leptomeningeal amyloidosis
Leptomeningeal amyloidosis occurs often in concurrent
with intracortical CAA in the human brain [3-7]. AsFigure 7 Schematic illustration of a hypothetic model for BACE1 elevation in
and leptomeningeal (panel B) amyloidosis. Arteriolar profile is used here to co
pathological events. BACE1 elevation first occurs in endothelial cells (EC), resu
This is followed by the damage of tight junctions (TJ) and blood brain barrier
The Aβ products and/or blood infiltration then induce SMC degeneration, an
manifested as aberrant sprouting and dystrophy. The invasion of the Aβ prod
of amyloidosis, cell degeneration and microbleeding. This process may end u
all degenerate (panel A). For leptomeningeal amyloidosis, we propose that th
breakdown, and SMC degeneration) potentiate BACE1 expression in the near
and meninge collectively contribute to the spread of amyloidosis along the leleptomeninge is enriched of blood vessels, it is reasonable
to consider leptomeningeal amyloidosis a form of CAA.
However, leptomeningeal Aβ deposition may spread along
the cerebral surface continuously rather than invariably be
associated with leptomeningeal vasculature or blood ves-
sels entering the cortex. In the present study we observe
BACE1 IR in cellular profiles along the pia, in addition to
vascular endothelial cells and perivascular dystrophic
neurites. Levels of BACE1 protein, activity and the imme-
diate products C99 are elevated in leptomeningeal lysates
from brains with pial amyloidosis relative to controls.
Using primary cell culture from human subjects, menin-
geal cells are found to express BACE1 and other amyloi-
dogenic protein. Therefore, meningeal cells could be one
of the cellular sources contributing Aβ that might deposit
locally in the leptomeninge.
A hypothetic model for angiopathic and leptomeningeal
β-amyloid deposition
Amyloidosis consists of a wide spectrum of conditions
with pathological protein deposition in the central and
peripheral systems [46]. Aβ deposition has been so far
predominantly, if not exclusively, characterized in the
central nerve system. Here we show BACE1 expression
in vascular endothelia, perivascular dystrophic neuritesvascular and brain-specific cellular elements in angiopathic (panel A)
nstruct the model to show the major relevant cellular components and
lting in Aβ rise and aggregation in the smooth muscle cell (SMC) layer.
, causing leakage of blood contents into the SMC layer (curved arrows).
d further a reactive response of the perivascular axonal terminals,
ucing dystrophic neurites into the vascular wall leads to a vicious cycle
p with a “burnout” stage whereby the ECs, SMCs and dystrophic neurites
e initial events (endothelial Aβ overproduction, Aβ aggregation, BBB
by meningeal cells. A vicious cycle of pathogenesis in the blood vessel
ptomeninge (panel B).
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geal amyloidosis in aged human cerebrum. The finding
of BACE1 elevation in perivascular neurites and menin-
geal cells appears of particular interest, and may imply
an anatomic basis underlying the brain specificity of vas-
cular and leptomeningeal β-amyloidosis.
Although definitively revealing the onset and evolu-
tion of a typical pathology would require time-lapsing
observation in vivo, staging cellular/histological alter-
ations is a general practice in pathology and clinic medi-
cine. Based on the current findings as discussed above,
we propose a dual-origin pathogenic model for angio-
pathic and leptomeningeal Aβ deposition in the human
brain (Figure 7). Stimulated by certain stress factors,
the endothelial cells (EC) start to over-express BACE1
(or APP as well), resulting in increased Aβ production
(Figure 7A). The EC-derived Aβ peptides are released
into blood as well as inside the vascular wall, causing a
damage of the tight junctions (TJs) and the blood brain
barrier. Vascular leakage and the soluble and insoluble
Aβ products cause smooth muscle cell (SMC) de-
generation. These events (cellular toxicity and space-
emptying effect) trigger a reactive response of the
perivascular axonal terminals, manifested by aberrant
sprouting and dystrophy, which is inherently associated
with BACE1 upregulation [25]. As the dystrophic neur-
ites invade into the vascular wall, they contribute more
Aβ products into the local environment. This eventually
leads to a vicious cycle of amyloidosis, cell degeneration
and microbleeding. At the end stage, cell components
including the SMCs, ECs and the dystrophic neurites
may all degenerate (“burn-out”), leaving the original
vascular site as a niche with concentrated insoluble Aβ
products. For the involvement of meningeal cells in
leptomeningeal amyloidosis, the initial events may be
similar to the above (Figure 7B). Vascular leakage and
Aβ products then potentiate BACE1 expression in men-
ingeal cells in the outer and inner barrier layers of the
arachnoid and on the pia (not illustrated), resulting in
Aβ overproduction and accumulation in the leptome-
ninge. A vicious pathogenic cycle eventually leads to a
spreading of amyloidosis along the brain surface.
Conclusions
The present study shows increased BACE1 immunore-
activity in vascular endothelia, perivascular dystrophic
neurites and meningeal cells in partnership with angio-
pathic and leptomeningeal Aβ deposition in postmor-
tem human brains. Elevations of BACE1 protein and
enzymatic activity in association with leptomeningeal
amyloidosis are verified biochemically. Primary cell
cultures from human biopsies indicate an endogenous
expression of BACE1 and other amyloidogenic proteins
in vascular endothelial and meningeal cells. Together,these findings suggest that both vascular and brain-
specific cellular components (neuronal terminals and
meningeal cells) may contribute to angiopathic and
leptomeningeal amyloidosis.
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